Lifecore Biomedical posted a GAAP net loss of $6.2 million, widening from the prior-year quarter; GAAP loss per diluted share was $0.19.
Revenue fell 6.2% from the prior-year quarter to $34.2 million, while GAAP gross profit slipped 13.64% to $12.1 million.
Non-GAAP adjusted EBITDA edged down 5.49% to $8.6 million; liquidity ended the quarter at $38.8 million, including $17.2 million cash.
The company signed six new programs in the quarter, including two commercial-stage programs; completed five customer audits and two regulatory inspections.
Lifecore reaffirmed its 2026 outlook for revenue of $120 million to $125 million and non-GAAP adjusted EBITDA of $20.5 million to $25 million.
LFCR•
